Core Viewpoint - Regeneron Pharmaceuticals, Inc. is set to report its third quarter 2025 financial and operating results on October 28, 2025, before the U.S. financial markets open [1] Group 1: Financial Reporting - The third quarter 2025 financial results will be announced before the market opens on October 28, 2025 [1] - A conference call and webcast will take place at 8:30 AM Eastern Time on the same day [1] Group 2: Conference Call Information - Participants can access the conference call live via webcast on Regeneron's 'Investors and Media' page [2] - Telephone participants must register in advance to receive a confirmation email with details on how to join the call [2] - A replay and transcript of the conference call will be available on the company's website for at least 30 days [2] Group 3: Company Overview - Regeneron is a leading biotechnology company focused on developing life-transforming medicines for serious diseases [3] - The company is known for its ability to translate scientific research into approved treatments and has a robust pipeline of product candidates [3] - Regeneron's medicines target a wide range of conditions, including eye diseases, cancer, and rare diseases [3] Group 4: Technological Advancements - Regeneron utilizes proprietary technologies like VelociSuite to develop optimized fully human antibodies and bispecific antibodies [4] - The company leverages data from the Regeneron Genetics Center to identify innovative treatment targets [4]

Core Insights - BridgeBio Pharma, Inc. is set to present significant findings related to its drug Acoramidis at the Heart Failure Society of America Annual Scientific Meeting 2025, highlighting its focus on genetic diseases [1][6]. Group 1: Clinical Presentations - A late-breaking clinical trial presentation will discuss the effect of Acoramidis on cardiovascular outcomes in patients with ATTR-CM, presented by Dr. Ahmad Masri on September 28 [2]. - An oral presentation will reveal that continuous treatment with Acoramidis significantly reduced the risk of all-cause mortality and cardiovascular-related hospitalization at month 42 for patients with transthyretin amyloidosis, presented by Dr. Lily Stern on September 27 [2]. Group 2: Poster Sessions - A poster session will present results showing that Acoramidis mitigates the rise in NT-proBNP levels compared to placebo in patients with variant transthyretin amyloid cardiomyopathy, presented by Dr. Nitasha Sarswat on September 27 [3]. - Another poster will discuss the effect of Acoramidis on cardiac conduction abnormalities in transthyretin amyloid cardiomyopathy, presented by Dr. Brett W. Sperry on September 27 [3]. - A poster will address state-level differences in the incidence of transthyretin amyloid cardiomyopathy among U.S. veterans after the introduction of disease-modifying therapy, presented by Dr. Sandesh Dev on September 28 [3]. Group 3: Product Information - Attruby™ (acoramidis) is indicated for treating cardiomyopathy associated with wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults, aimed at reducing cardiovascular death and related hospitalizations [4]. Group 4: Safety Information - Adverse reactions reported for Attruby include diarrhea (11.6% vs 7.6% for placebo) and upper abdominal pain (5.5% vs 1.4% for placebo), with most being mild and resolving without discontinuation of the drug [5].

Core Viewpoint - Regeneron Pharmaceuticals, Inc. will present at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, 2025, at 7:00 a.m. ET [1] Company Overview - Regeneron is a leading biotechnology company focused on inventing, developing, and commercializing life-transforming medicines for serious diseases [3] - The company was founded and is led by physician-scientists, emphasizing its ability to translate scientific research into approved treatments and product candidates [3] - Regeneron's medicines and pipeline target various conditions, including eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases [3] Technological Advancements - Regeneron utilizes proprietary technologies, such as VelociSuite, to produce optimized fully human antibodies and new classes of bispecific antibodies [4] - The company is advancing drug development through data-powered insights from the Regeneron Genetics Center and pioneering genetic medicine platforms [4] - These innovations enable Regeneron to identify innovative targets and complementary approaches for potentially treating or curing diseases [4]

PALO ALTO, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will host fireside chats at the following healthcare investor conferences: Wells Fargo Healthcare Conference, Boston, MA: Fireside chat on Wednesday, September 3 at 9:30 am ETCantor Global Healthcare Conference – New York, NY: Fireside chat on Thursday, September 4 at ...

Core Insights - Eli Lilly and Company has successfully completed the acquisition of Verve Therapeutics, a clinical-stage company focused on genetic medicines for cardiovascular disease [1] - The acquisition is expected to transform treatment paradigms for millions of patients by providing lifelong cardiovascular risk reduction through a single treatment [2] Company Overview - Eli Lilly has been a pioneer in medical discoveries for nearly 150 years, helping tens of millions globally with its medicines [2] - The company is focused on addressing significant health challenges, including diabetes care, obesity, Alzheimer's disease, immune system disorders, and difficult-to-treat cancers [2] Strategic Implications - The integration of Verve Therapeutics is anticipated to enhance Lilly's capabilities in developing innovative genetic medicines for cardiometabolic diseases [2] - The acquisition aligns with Lilly's mission to make life better for millions by advancing clinical trials and ensuring medicine accessibility [2]

Core Viewpoint - Eli Lilly and Verve Therapeutics have completed a tender offer for Verve's common stock, with a purchase price of $10.50 per share and a contingent value right potentially worth up to $3.00 per share, which expired on July 23, 2025 [1][2]. Group 1: Acquisition Details - The tender offer resulted in 49,882,464 shares being validly tendered, representing approximately 55.7% of the outstanding shares [2]. - All conditions for the acquisition have been satisfied, and Lilly will proceed to pay for the validly tendered shares [2]. - The acquisition is expected to be finalized on July 25, 2025, in accordance with the definitive agreement [3]. Group 2: Company Profiles - Verve Therapeutics is a clinical-stage company focused on developing genetic medicines for cardiovascular diseases, with lead programs targeting key drivers of atherosclerosis [4]. - Lilly is a long-established pharmaceutical company dedicated to advancing healthcare solutions across various significant health challenges, including diabetes, obesity, Alzheimer's disease, and cancer [5].

Core Insights - BridgeBio Pharma, Inc. is set to release its second quarter financial results and business updates on August 5, 2025, after market close [1] - A conference call will be held at 4:30 pm ET on the same day to discuss the financial results and program updates [1] Company Overview - BridgeBio Pharma, Inc. is a biopharmaceutical company focused on discovering, creating, testing, and delivering transformative medicines for genetic diseases [3] - The company was founded in 2015 and has a pipeline that includes programs from early science to advanced clinical trials [3] - BridgeBio's team consists of experienced professionals dedicated to applying advances in genetic medicine to benefit patients [3]

Core Viewpoint - A class action lawsuit has been filed against Sarepta Therapeutics, Inc. for allegedly making false and misleading statements regarding its gene therapy product ELEVIDYS during the specified Class Period [1][2]. Allegations in the Complaint - Sarepta is accused of misrepresenting the safety of ELEVIDYS, despite serious risks associated with the product [7]. - The company allegedly failed to detect or disclose severe adverse events during clinical trials [7]. - It is claimed that Sarepta withheld material information that led to halted dosing, increased regulatory scrutiny, and suspension of shipments [7]. - The company is also said to have lacked a reasonable basis for positive statements about ELEVIDYS's safety and potential for expanded use [7]. Key Events and Stock Impact - Investors who purchased Sarepta securities during the Class Period and suffered losses have until August 25, 2025, to request the Court to appoint them as lead plaintiff [3].

Core Insights - Regeneron Pharmaceuticals, Inc. will report its second quarter 2025 financial and operating results on August 1, 2025, before U.S. markets open [1] - A conference call and webcast will be held at 8:30 AM Eastern Time on the same day [1][2] Company Overview - Regeneron is a leading biotechnology company focused on inventing, developing, and commercializing life-transforming medicines for serious diseases [3] - The company has a strong pipeline of approved treatments and product candidates, primarily developed in-house, targeting various conditions including eye diseases, cancer, and rare diseases [3] Technological Advancements - Regeneron utilizes proprietary technologies like VelociSuite to produce optimized fully human antibodies and bispecific antibodies [4] - The company leverages data-powered insights from the Regeneron Genetics Center to identify innovative treatment targets and approaches [4]

Company Overview - BridgeBio Pharma, Inc. is a biopharmaceutical company focused on discovering, creating, testing, and delivering transformative medicines for genetic diseases [3] - Founded in 2015, the company has a pipeline that includes programs from early science to advanced clinical trials [3] - The team consists of experienced drug discoverers, developers, and innovators dedicated to applying advances in genetic medicine [3] Upcoming Event - Members of BridgeBio's management team will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 on June 9 at 8:40 am ET [1] - A live webcast of the presentation will be available on the company's website, with a replay accessible for 30 days post-event [2]